DEF 14A: Adicet Bio Seeks Stockholder Approval for Key Proposals at 2024 Annual Meeting

Adicet Bio is holding its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to vote on several proposals, including director elections, amendments to stock option and incentive plans, and an increase in authorized shares.

Summary

• Adicet Bio, Inc. will hold its 2024 Annual Meeting of Stockholders online on June 5, 2024, at 5:00 p.m. Eastern Time.
• Stockholders of record as of April 9, 2024, are entitled to vote on several key proposals.
• The proposals include the election of two class III directors, Michael G. Kauffman, M.D., Ph.D. and Andrew Sinclair, Ph.D., to serve until the 2027 annual meeting.
• A key proposal is to approve an amendment to the Adicet Bio, Inc. Second Amended and Restated 2018 Stock Option and Incentive Plan to increase the number of shares of common stock authorized for issuance under the plan by 5,000,000 shares of common stock.
• Another proposal seeks to approve an amendment to the Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000.
• Stockholders will also vote on an amendment to the Third Amended and Restated Certificate of Incorporation to limit the liability of certain officers as permitted by Delaware law.
• Additionally, there will be non-binding advisory votes on executive compensation and the frequency of future advisory votes on executive compensation.
• Finally, stockholders will vote to ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The board of directors recommends voting in favor of all proposals except for Proposal 6, where they recommend a vote for every one year as the frequency of future advisory votes on executive compensation.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining proposals for stockholder vote. The sentiment is neutral to slightly positive, as the proposals aim to provide the company with greater flexibility and improve corporate governance.

Positives

• The proposed increase in authorized shares provides the company with greater flexibility for future corporate needs, including raising capital and strategic transactions.
• The amendment to limit officer liability could enhance the company's ability to attract and retain qualified officers.
• The board is committed to sound corporate governance by providing stockholders with the opportunity to vote on executive compensation and its frequency.

Negatives

• Future issuances of common stock could have a dilutive effect on earnings per share, book value per share, voting power, and percentage interest of holdings of current stockholders.
• The availability of additional shares of common stock for issuance could, under certain circumstances, discourage or make more difficult efforts to obtain control of the company.

Risks

• If the company fails to secure an increase to the 2018 Plan, it may need to utilize other types of incentive compensation structures, potentially increasing cash compensation expenses.
• The payments and benefits provided to certain executives in connection with a change in control may not be eligible for a federal income tax deduction for the company pursuant to Section 280G of the Internal Revenue Code of 1986, as amended, or the Code, and may subject certain executives to an excise tax under Section 4999 of the Code.

Future Outlook

The company anticipates that if the request to increase the share reserve is approved by our stockholders, it will be sufficient to provide equity incentives to attract, retain, and motivate executives and employees for the next one to two years; however the share reserve may last longer or shorter depending on our hiring needs and fluctuations in our stock price, among other things.

Industry Context

The use of equity compensation and officer exculpation clauses are common practices among public companies, particularly in the biotechnology industry, to attract and retain talent and manage risk.

Comparison to Industry Standards

• The company's compensation practices are benchmarked against a peer group of similarly-sized companies within the pharmaceuticals, biotechnology, and life sciences industry.
• The company's total overhang of approximately 19.3 million shares represents approximately 23.5% of common stock outstanding, positioning us slightly below the median of similarly-sized industry peer companies.

Corporate Governance

Related Party Transactions

• Certain investors, including entities affiliated with OrbiMed and Abingworth, purchased shares in the January 2024 underwritten public offering.
• Dr. Gordon, a member of the Board of Directors, is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors.
• Dr. Sinclair, a member of the Board of Directors, is a partner at Abingworth LLP.

Stakeholder Impact

• Approval of the proposals could impact shareholders through potential dilution and changes in voting power.
• Employees may be affected by changes to the stock option and incentive plans.
• The company's ability to attract and retain qualified officers could be enhanced by limiting officer liability.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on June 5, 2024.
• If approved, the company will file the Certificate of Amendment with the Secretary of State of the State of Delaware.
• The company will continue to monitor and adjust its compensation practices to remain competitive and align with stockholder interests.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Stock Options, Authorized Shares, KPMG, Director Election, Adicet Bio